G. Wallraven

发表

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

D. Rao, N. Senzer, J. Nemunaitis, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

N. Senzer, J. Nemunaitis, A. Tong, 2011, Clinical Cancer Research.

Compassionate approval process for experimental gene-based products.

J. Nemunaitis, G. Wallraven, P. Maples, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

J. Nemunaitis, R. Barrington, G. Wallraven, 2021, Vaccines.

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

J. Nemunaitis, M. Barve, G. Wallraven, 2021, Vaccines.

Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response

J. Nemunaitis, J. Herron, G. Wallraven, 2020, Cancer Science & Research.

Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

D. Rao, N. Senzer, J. Nemunaitis, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.

D. Rao, N. Senzer, J. Nemunaitis, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

J. Nemunaitis, M. Barve, G. Wallraven, 2022, Clinical Medicine Insights. Oncology.

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

B. Monk, J. Nemunaitis, E. Galanis, 2021, Cancer Gene Therapy.

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

B. Monk, N. Senzer, J. Nemunaitis, 2022, Communications Medicine.

Assessment of Low Dose Vigil ® Engineered Autologous Tumor Cell ( EATC ) Immunotherapy in Patients with Advanced Solid Tumors

D. Rao, N. Senzer, J. Nemunaitis, 2017 .

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.

B. Monk, J. Nemunaitis, R. Coleman, 2021, Gynecologic oncology.

Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.

P. Stephens, D. Rao, N. Senzer, 2017, Journal of pediatric hematology/oncology.

Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.

D. Rao, N. Senzer, J. Nemunaitis, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer

D. Rao, N. Senzer, J. Nemunaitis, 2013 .

Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer

D. Rao, N. Senzer, P. Beitsch, 2013 .

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

N. Senzer, J. Nemunaitis, R. Mennel, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I Trial of "bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer.

D. Rao, N. Senzer, J. Nemunaitis, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.

N. Senzer, J. Nemunaitis, L. West, 2016, Gynecologic oncology.

Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma

N. Senzer, J. Nemunaitis, P. Beitsch, 2016 .

Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients

R. Coleman, B. Slomovitz, J. Bottsford-Miller, 2020, Gynecologic Oncology.

Pilot trial of vigil immunotherapy in Ewing’s sarcoma.

N. Senzer, J. Nemunaitis, R. Mennel, 2015 .

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance

N. Senzer, J. Nemunaitis, M. Barve, 2020, Gynecologic oncology reports.

Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer

B. Monk, J. Nemunaitis, E. Galanis, 2021, Cancer Gene Therapy.

Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.

B. Monk, N. Senzer, J. Nemunaitis, 2021, Gynecologic oncology.

Cancer of the Liver

N. Senzer, J. Nemunaitis, B. Pappen, 2014 .

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA

B. Crompton, J. Nemunaitis, L. Wexler, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of Vigil ® DNA engineered immunotherapy asmaintenance in advanced stage ovarian cancer

N. Senzer, J. Nemunaitis, L. West, 2016 .

Gemogenovatucel-T (Vigil) Immunotherapy as Maintenance in Frontline Stage III/IV Ovarian Cancer (VITAL): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

B. Monk, J. Nemunaitis, J. Chan, 2021 .

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.

B. Monk, J. Nemunaitis, J. Chan, 2020, The Lancet. Oncology.

A bi-shRNAfurin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors.

K. Neville, N. Senzer, J. Nemunaitis, 2017 .

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine

N. Senzer, J. Nemunaitis, B. Pappen, 2013, Gene Therapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy.

G. Wallraven, L. Stanbery, E. Bognar, 2024, Future oncology.